| Hemopoietins in oncology: factoring out myelosuppression |
| JD Griffin |
|
JCO Feb 1 1989: 151–155.
[PDF]
|
 |
| What is the choice of treatment for hairy cell leukemia? |
| HM Golomb, MJ Ratain, and J Moormeier |
|
JCO Feb 1 1989: 156–158.
[PDF]
|
|
|
Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor |
| |
F Herrmann, G Schulz, A Lindemann, W Meyenburg, W Oster, D Krumwieh, and R Mertelsmann |
| |
JCO Feb 1 1989: 159–167.
[Abstract]
[PDF]
|
|
|
Pentostatin in the treatment of advanced hairy cell leukemia |
| |
EH Kraut, BA Bouroncle, and MR Grever |
| |
JCO Feb 1 1989: 168–172.
[Abstract]
[PDF]
|
|
|
Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses |
| |
FJ Meyers, J Welborn, JP Lewis, and N Flynn |
| |
JCO Feb 1 1989: 173–178.
[Abstract]
[PDF]
|
|
|
Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease |
| |
S Jagannath, JO Armitage, KA Dicke, SL Tucker, WS Velasquez, K Smith, WP Vaughan, A Kessinger, LJ Horwitz, and FB Hagemeister |
| |
JCO Feb 1 1989: 179–185.
[Abstract]
[PDF]
|
|
|
Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution |
| |
SB Murphy, DL Fairclough, RE Hutchison, and CW Berard |
| |
JCO Feb 1 1989: 186–193.
[Abstract]
[PDF]
|
|
|
Hemorrhagic cystitis following high-dose chemotherapy and bone marrow transplantation in children with malignancies: incidence, clinical course, and outcome |
| |
L Brugieres, O Hartmann, JP Travagli, E Benhamou, JL Pico, D Valteau, C Kalifa, C Patte, F Flamant, and J Lemerle |
| |
JCO Feb 1 1989: 194–199.
[Abstract]
[PDF]
|
|
|
Results of intensive therapy in children with localized alveolar extremity rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study |
| |
R Heyn, M Beltangady, D Hays, W Lawrence, Jr, W Newton, Jr, W Crist, M Tefft, and HM Maurer |
| |
JCO Feb 1 1989: 200–207.
[Abstract]
[PDF]
|
|
|
Therapy for localized Ewing's sarcoma of bone |
| |
FA Hayes, EI Thompson, WH Meyer, L Kun, D Parham, B Rao, M Kumar, M Hancock, L Parvey, and L Magill |
| |
JCO Feb 1 1989: 208–213.
[Abstract]
[PDF]
|
|
|
A prospective study of Hickman/Broviac catheters and implantable ports in pediatric oncology patients |
| |
J Mirro, Jr, BN Rao, DC Stokes, BA Austin, M Kumar, GV Dahl, M Colten, L Balas, M Rafferty, and M Hancock |
| |
JCO Feb 1 1989: 214–222.
[Abstract]
[PDF]
|
|
|
Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma |
| |
GP Sutton, FB Stehman, LH Einhorn, LM Roth, JA Blessing, and CE Ehrlich |
| |
JCO Feb 1 1989: 223–229.
[Abstract]
[PDF]
|
|
|
Intraarterial cisplatin and concurrent radiation for locally advanced bladder cancer |
| |
L Eapen, D Stewart, C Danjoux, P Genest, N Futter, D Moors, A Irvine, J Crook, S Aitken, and L Gerig |
| |
JCO Feb 1 1989: 230–235.
[Abstract]
[PDF]
|
|
|
Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy |
| |
KK Matthay, HN Sather, RC Seeger, GM Haase, and GD Hammond |
| |
JCO Feb 1 1989: 236–244.
[Abstract]
[PDF]
|
|
|
High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group |
| |
SN Wolff, RH Herzig, JW Fay, CF LeMaistre, D Frei-Lahr, J Lowder, B Bolwell, L Giannone, and GP Herzig |
| |
JCO Feb 1 1989: 245–249.
[Abstract]
[PDF]
|
|
|
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma |
| |
B Fisher, BS Packard, EJ Read, JA Carrasquillo, CS Carter, SL Topalian, JC Yang, P Yolles, SM Larson, and SA Rosenberg |
| |
JCO Feb 1 1989: 250–261.
[Abstract]
[PDF]
|
|
|
Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole |
| |
R Goel, SM Cleary, C Horton, FM Balis, S Zimm, S Kirmani, and SB Howell |
| |
JCO Feb 1 1989: 262–269.
[Abstract]
[PDF]
|
|
|
Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerations |
| |
PA Reece, I Stafford, RL Abbott, C Anderson, J Denham, S Freeman, RG Morris, PG Gill, and CL Olweny |
| |
JCO Feb 1 1989: 270–275.
[Abstract]
[PDF]
|
|
|
A phase I clinical trial of recombinant interleukin-2 by periodic 24- hour intravenous infusions |
| |
SP Creekmore, JE Harris, TM Ellis, DP Braun, II Cohen, N Bhoopalam, PF Jassak, MA Cahill, CL Canzoneri, and RI Fisher |
| |
JCO Feb 1 1989: 276–284.
[Abstract]
[PDF]
|
|
| Abdominal lymphoma and intestinal perforation |
| R Rivera-Luna and G Martinez Guerra |
|
JCO Feb 1 1989: 285–286.
[PDF]
|
|
